Sulfonylureas and fracture risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Rev Clin Esp (Barc)Jun 10, 2026 (epub)
Clinical ResearchEndocrinology

L Xu, R Yuan, H Yue et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the association between sulfonylureas and fracture risk in patients with type 2 diabetes mellitus (T2DM). Analyzing data from 12 observational studies with 5,854,139 patients, the study found that sulfonylurea use was significantly linked to an increased overall fracture risk (RR = 1.28) and a higher risk of osteoporotic fractures (RR = 1.38).

Key findings

  • Sulfonylurea use is associated with a 28% increased risk of overall fractures (RR = 1.28).
  • The risk of osteoporotic fractures is increased by 38% (RR = 1.38).
  • Hip fracture risk increases by 23% (RR = 1.23).
  • Vertebral fracture risk shows a 47% increase (RR = 1.47).

Why it matters

Understanding the fracture risk associated with sulfonylureas is crucial for clinicians managing patients with T2DM, as it may influence treatment decisions and patient safety.

Source

PubMed · PMID 42269923

Published in Rev Clin Esp (Barc). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.